JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Robert C. Robbins
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, M.
Right arrow Articles by Robbins, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, M.
Right arrow Articles by Robbins, R. C.
Related Collections
Right arrow Transplantation - heart

J Thorac Cardiovasc Surg 2005;129:1160-1167
© 2005 The American Association for Thoracic Surgery

Cardiothoracic Transplantation

Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators

Masashi Tanaka, MDa,*, Feny Gunawana, Raya D. Terrya, Koichi Inagaki, MD, PhDb, Anthony D. Caffarelli, MDa, Grant Hoyta, Philip S. Tsao, PhDc, Daria Mochly-Rosen, PhDb, Robert C. Robbins, MDa

a Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, Calif
b Department of Molecular Pharmacology, Stanford University Medical Center, Stanford, Calif
c Department of Cardiovascular Medicine, Stanford University Medical Center, Stanford, Calif

Received for publication June 17, 2004; revisions received September 8, 2004; accepted for publication September 20, 2004.

* Address for reprints: Masashi Tanaka, MD, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Falk Cardiovascular Research Center, Stanford, CA 94305 (E-mail: masahi{at}omiya.jichi.ac.jp).

OBJECTIVE: Transplanted hearts subjected to prolonged ischemia develop ischemia-reperfusion injury and graft coronary artery disease. To determine the effect of {delta}-protein kinase C and {epsilon}-protein kinase C on ischemia-reperfusion injury and the resulting graft coronary artery disease induced by prolonged ischemia, we used a {delta}-protein kinase C-selective inhibitor peptide and an {epsilon}-protein kinase C-selective activator peptide after 30 or 120 minutes of ischemia.

METHODS: Hearts of piebald viral glaxo (PVG) rats were heterotopically transplanted into allogeneic August Copenhagen Irish (ACI) rats. After cardioplegic arrest of the donor heart, {epsilon}-protein kinase C activator was injected antegrade into the coronary arteries. Hearts were procured and bathed in {epsilon}-protein kinase C activator, and before reperfusion, {delta}-protein kinase C inhibitor was injected into the recipient inferior vena cava. Controls were treated with saline. To analyze ischemia-reperfusion injury, grafts were procured at 4 hours after transplantation and analyzed for superoxide generation; myeloperoxidase activity; tumor necrosis factor {alpha}, interleukin 1ß, and monocyte/macrophage chemoattractant protein 1 production; and cardiomyocyte apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and caspase 2, 3, 8, and 9 activity. To analyze graft coronary artery disease, another set of animals underwent equal ischemic times and treatment strategies and then after 90 days were analyzed for graft coronary artery disease indexes.

RESULTS: All measures of ischemia-reperfusion injury and graft coronary artery disease after 120 minutes of ischemia in the saline-treated group were significantly increased relative to those observed after 30 minutes of ischemia. It is important to note that all ischemia-reperfusion injury parameters and graft coronary artery disease indexes decreased significantly in the protein kinase C regulator-treated group in comparison to saline-treated controls; additionally, these values were equivalent to those in saline-treated controls with 30 minutes of ischemia.

CONCLUSIONS: Combined treatment with {epsilon}-protein kinase C activator and {delta}-protein kinase C inhibitor reduces ischemia-reperfusion injury and decreases the resulting graft coronary artery disease induced by prolonged ischemia.




This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
S. S. Palaniyandi, L. Sun, J. C. B. Ferreira, and D. Mochly-Rosen
Protein kinase C in heart failure: a therapeutic target?
Cardiovasc Res, May 1, 2009; 82(2): 229 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
K. Inagaki, E. Churchill, and D. Mochly-Rosen
Epsilon protein kinase C as a potential therapeutic target for the ischemic heart
Cardiovasc Res, May 1, 2006; 70(2): 222 - 230.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.